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Lymphatic filariasis has been targeted for elimination by 2020, and a threshold of 65% coverage of mass drug
administration (MDA) has been adopted by the Global Programme to Eliminate Lymphatic Filariasis (GPELF).
A recent review by Babu and Babu of 36 studies of MDA for lymphatic filariasis in India found that coverage, defined
as receipt of tablets, ranged from 48.8 to 98.8%,while compliance, defined as actual ingestion of tablets, was 22%
lower on average. Moreover, the denominator for these coverage figures is the eligible, rather than total, population.
By contrast, the 65% threshold, in the original modelling study, refers to ingestion of tablets in the total population.
This corresponds to GPELF’s use of ‘epidemiological drug coverage’ as a trigger for the Transmission Assessment
Surveys (TAS), which indicatewhether to proceed to post-MDA surveillance. The existence of less strict definitions of
‘coverage’ should not lead to premature TAS that could impair MDA’s sustainability.
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In 1997, the World Health Assembly called for lymphatic filariasis
to be eliminated as a public health problem. WHO’s response
included the launch of the Global Programme to Eliminate
Lymphatic Filariasis (GPELF) in 2000. An important tool for elimin-
ation is mass drug administration (MDA) with albendazole com-
bined with either ivermectin or diethylcarbamazine citrate (DEC),
for which the minimum effective coverage of the total population
is considered to be 65%.1 Published in 2010, this GPELF report is
subtitled ‘halfway towards eliminating lymphatic filariasis’, in ref-
erence to the target elimination date of 2020. In 2015, we are
three-quarters of the way.
The 65% threshold for effective coverage is based on a model-
ling study which, for the specific setting of Pondicherry (India),
estimated that eight rounds of ivermectin would give 99% prob-
ability of elimination.2 For combination therapy, this study found
that five or six roundsmight be sufficient. The GPELF recommends
carrying out a Transmission Assessment Survey (TAS) after at least
five rounds of MDA, in order to determine whether the area
requires further rounds of MDA, or can proceed to the surveillance
stage.3 The most recent GPELF progress report shows that, of
73 filariasis-endemic countries, 60 have started MDA, of which
15 have since stopped MDA nationwide.4
The recent review by Babu and Babu of 36 studies of MDA for
lymphatic filariasis in India highlights the divergence of some
reported coverage information from the ‘effective coverage’ spe-
cified by the GPELF.5 Combining urban and rural areas within each
study, coverage ranged from 48.8 to 98.8%. India’s National
Vector Borne Disease Control Programme indicates coverage of
MDA (DEC+albendazole) of between 82 and 88%, for the years
2006–2013.6 Provisional GPELF data from India in 2013 showed
coverage of 71.4% of the target population.4
However, coverage is not ‘effective’ if, for example, it includes
delivery of drugs that are not subsequently ingested. Babu and
Babu noted that the literature distinguishes ‘coverage’ (the pro-
portion of eligible people who received the antifilarial tablets)
from ‘compliance’ (the proportion of eligible people who actually
ingested the tablets). The distinction would be immaterial if the
drugs were almost always ingested, but Babu and Babu found
that, on average, the difference between coverage and compli-
ance was 22%.
Defining coverage in terms of the eligible population corre-
sponds to ‘drug coverage’ as defined in the WHO TAS manual.7
By contrast, ‘epidemiological drug coverage (programme cover-
age)’ refers to the total population.1,7 Stolk et al.’s coverage of
65% also refers to the total population. They note that the pres-
ence of a group who never ingest the MDA drugs, for example due
to ineligibility, is an ‘important threat to the effectiveness of mass
treatment’. In India, those pregnant, below 2 years of age or
seriously ill are not eligible.
Eligible individuals consistently declining MDA also contribute
to this threat to effectiveness. In total, 29 of the 36 reviewed stud-
ies reported factors associated with low compliance, the most
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common being fear of side effects, lack of perceived need for
the drugs and being away from home when the drugs were
delivered to relatives. These are similar to those found in a global
review of compliance,8 whose five recommendations included
tailoring programs to local conditions, minimizing the impact of
adverse events and promoting the broader benefits of the MDA
program.
To achieve elimination, the required duration, and the level of
effective coverage of MDA can be expected to vary between set-
tings, perhaps greatly. One key determinant is likely to be vectorial
capacity, which depends on characteristics of the local mosqui-
toes, such as density and biting rate. Other elimination and eradi-
cation programmes are likely to be instructive. For example, the
endgame of Guinea worm (dracunculiasis) eradication suggests
that the ‘last inch as opposed to the last mile’ will ‘be the most
costly and require special efforts’.9 Several studies on filariasis
MDA highlight the existence of areas refractory to control, often
called ‘hotspots’.10,11 These studies note the need for flexible con-
trol strategies in such areas, in terms of TAS methodology and
MDA duration. What should not be flexible are definitions of elim-
ination metrics such as coverage. Decisions on proceeding to
transmission assessment (TAS) should be based on GPELF’s ‘epi-
demiological drug coverage’, and subject to a verification survey.7
Otherwise, as Babu and Babu note, TAS surveys may be done pre-
maturely. Any additional rounds of MDA would then impose sus-
tained, possibly unexpected, strain on fund-raising and staff
morale, which could cause effectiveness to falter.
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